Latest Asarina Pharma News & Updates

See the latest news and media coverage for Asarina Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Asarina Pharma

Swedish biotech developing neuroendocrinological disorder treatments

asarinapharma.com
Headquarters
Haga, Sweden
Founded year
2006
Company type
Private company
Number of employees
3–10

Latest news about Asarina Pharma

Company announcements

  • Asarina Pharma

    Asarina Pharma sells Sepranolone assets to Relmada Therapeutics

    Relmada acquires all rights to continue clinical development in Tourette Syndrome. Asarina plans to liquidate following the asset transfer.

  • Asarina Pharma

    Asarina Pharma applies for delisting of shares

    Following a decision for voluntary liquidation on August 21, 2024, the board applies for delisting from Nasdaq First North Growth Market. Trading end date to be announced separately.

  • Asarina Pharma

    Asarina Pharma resolves voluntary liquidation

    The extraordinary general meeting on 21 August 2024 approves liquidation effective 1 December 2024, pending payments to Danish subsidiary.

  • Asarina Pharma

    Asarina Pharma announces extraordinary general meeting

    The board proposes liquidation due to negative equity and failed partnership efforts for Sepranolone. Meeting is on 21 August 2024.

Unlock all announcements with a

Media coverage

  • Life Science Sweden

    Asarina gets US patent for treatment against Tourette's and gambling addiction

    My account Log in {{ truncateString(window.visitor.corporateClient.name, 12) }}{{ truncateString(window.visitor.corporateClient.name, 20) }} {{ truncateString ...

  • Dagens industri

    Asarina Pharma reduced the loss

    Asarina Pharma reports for the third quarter of the year an operating result of -8.1 million kronor (-17.5) and an earnings per share of -0:40 kronor (-0:90). The past...

  • Dagens industri

    The biotech company Asarina Pharma aims for the USA

    Drug development is always risky, he admits. The statistical risk that a phase 2b study fails is 35 percent, but when it comes to Asarina Pharma's current study...

  • Life Science Sweden

    Receives funding for study on severe PMS

    The biotech company Asarina Pharma (formerly Umecrine Mood) announces today Wednesday that the company has raised new capital to conduct a phase IIb study with its drug candidate...

Unlock all articles with a

Never miss news about Asarina Pharma

Track Asarina Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Asarina Pharma competitors & trending companies

Browse news for competitors to Asarina Pharma and other trending companies.